Hologic reported a revenue of $1,013.1 million for the first quarter of fiscal year 2024, a decrease of 5.7% compared to the prior year, but exceeded their guidance. GAAP diluted EPS was $1.03 and non-GAAP diluted EPS was $0.98, also exceeding guidance. Total organic revenue growth excluding COVID-19 was 5.2% in constant currency.
Revenue of $1,013.1 million decreased (5.7%) for the quarter, or (6.4%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period.
Excluding COVID-19 revenues, total organic revenue grew 6.1%, or 5.2% on a constant currency basis despite the prior year period including four extra selling days.
Breast Health revenue increased 13.0%, or 12.2% in constant currency, primarily due to higher capital equipment revenue compared to the prior year period as supply chain headwinds impacted our ability to manufacture sufficient units to meet demand in fiscal Q1 2023.
Cash flow from operations remained strong in the first quarter at $220.0 million.
Hologic is guiding for the second quarter of fiscal year 2024 with revenue between $990 million and $1,010 million and non-GAAP EPS between $0.95 and $1.00. For the full fiscal year 2024, Hologic is guiding for revenue between $3,990 million and $4,065 million and non-GAAP EPS between $3.97 and $4.12.
Visualization of income flow from segment revenue to net income